GLUE — Monte Rosa Therapeutics Share News
0.000.00%
Last trade - 00:00- $947.83m
- $326.73m
- $123.67m
Brief: Monte Rosa Therapeutics Q1 Loss Per Share USD 0.65
Brief: Monte Rosa Therapeutics Presents Preclinical Data From Gspt1 Degrader Program Focused On Myc-Driven Cancers At Aacr 2023
Brief: Monte Rosa Therapeutics Appoints Jan Skvarka To Board Of Directors
Brief: Monte Rosa Therapeutics Announces Fourth Quarter 2022 Financial Results
Brief: Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
Brief: Monte Rosa Therapeutics Outlines Progress Across Portfolio Of Molecular Glue Degraders
Brief: Monte Rosa Therapeutics Reports Third Quarter Results
Brief: Monte Rosa Therapeutics Announces First Patient Dosed In Phase 1/2 Clinical Trial Evaluating MRT-2359 For Treatment Of MYC-Driven Tumors
Brief: Monte Rosa Therapeutics announces FDA clearance of investigational new drug application for MRT-2359, GSPT1-directed molecular glue degrader
U.S. RESEARCH ROUNDUP- Advance Auto Parts, Middleby, Union Pacific
U.S. RESEARCH ROUNDUP- PLx pharma, Vroom, Walmart
Brief: Monte Rosa Therapeutics Reports Second Quarter 2022 Financial Results
Brief: Monte Rosa Therapeutics Inc Files For Mixed Shelf Of Up To $300 Million - SEC Filing
Brief: Monte Rosa Therapeutics Reports First Quarter 2022 Financial Results And Business Updates
Brief: Monte Rosa Says Year-End Cash, Cash Equivalents To Provide Runway Into Late 2024
Brief: Monte Rosa Therapeutics And Yeda Announce License And Research Collaboration
Brief: Monte Rosa Therapeutics Announces First Development Candidate And Reports Q3 2021 Financial Results
Brief: Monte Rosa Therapeutics Announces Addition To Russell 2000 And Russell 3000 Indexes
Monte Rosa Therapeutics Inc reports results for the quarter ended in June - Earnings Summary